Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 2/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29538429 | 1.00 | HTR2A (0.39) | HTR2AHTR2CNOTUMSLC6A2KMT2A | |
| SCHEMBL30864980 | 0.85 | HTR2A (0.40) | HTR2AHTR2CNOTUMSLC6A2KMT2A | |
| SCHEMBL3203395 | 0.72 | HTR2A (0.35) | HTR2AHTR2CNOTUM | |
| SCHEMBL1383923 | 0.71 | HTR2A (0.43) | HTR2AHTR2CNOTUMKMT2ADAO | |
| SCHEMBL2764410 | 0.67 | HTR2A (0.51) | HTR2AHTR2CNOTUMADRA2A | |
| SCHEMBL1864062 | 0.67 | HTR2A (0.40) | HTR2AHTR2CNOTUMKMT2ADAO | |
| SCHEMBL29851785 | 0.67 | HTR2A (0.40) | HTR2AHTR2CNOTUMKMT2ADAO | |
| SCHEMBL14382337 | 0.66 | HTR2A (0.45) | HTR2AHTR2CNOTUMKMT2A | |
| SCHEMBL3211491 | 0.63 | HTR2A (0.37) | HTR2AHTR2CNOTUMKMT2A | |
| Hydroxyamine SCHEMBL9656520 | 0.63 | HTR2A (0.37) | HTR2AHTR2CNOTUMKMT2ADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | claimed |
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | EMCURE PHARMACEUTICALS LIMITED (IN) | 2019-01-31 | — | — | US | disclosed |
| US-7498350-B2 | Oxazolidinones as antibacterial agents | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| US-20070281916-A1 | Substituted isoxazolines and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | disclosed |
| EP-1286998-B2 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| US-7199143-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-7141583-B2 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| US-7081538-B1 | Substituted isoxazolines and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2006-07-25 | — | — | US | disclosed |
| EP-1385844-B1 | OXAZOLIDINONES CONTAINING A SULFONIMID GROUP AS ANTIBIOTICS | ASTRAZENECA AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2002080841-A2 | ANTIBACTERIAL OXAZOLIDINONES WITH A CYCLIC SULPHILIMINE OR SULPHOXIMINE | ASTRAZENECA AB (SE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002081468-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1242416-A1 | SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| US-6362191-B1 | ANTIBIOTICS | ZENECA LTD. (GB) | 2002-03-26 | — | — | US | disclosed |
| WO-2001081350-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-01 | — | — | WO | disclosed |
| EP-1121358-A1 | HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS | AstraZeneca AB (SE) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001040222-A1 | SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000021960-A1 | HETEROCYCLYL AMINO METHYLOXA ZOLIDINONES AS ANTIBACTERIALS | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | HTR2A 2024/4885HTR2C 1085/4885NOTUM 1494/4885 |
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | IDO1, IDO2, TDO2 | HTR2A 162/4885HTR2C 193/4885NOTUM 2065/4885 |
| US-20070281916-A1 | Substituted isoxazolines and their use as antibacterial agents | CYP2S1, CYP3A7, CYP3A5 | HTR2A 1690/4885HTR2C 279/4885NOTUM 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.